Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Apr 26, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the connection between the gut bacteria (microbiota) and the risk of colorectal polyps returning after they have been removed (polypectomy). Researchers want to study the unique characteristics of gut bacteria in patients who have had high-risk polyps and see how these bacteria relate to the chances of the polyps coming back. By doing this, they hope to create a tool that can help predict which patients are at higher risk for recurrence based on their gut bacteria and other substances produced by these bacteria (metabolites).

To join the study, participants need to be between 40 and 75 years old and have undergone a colonoscopy that found at least one high-risk colorectal polyp. However, some individuals won’t be able to participate, such as those with serious health issues that could interfere with the study or those who have had certain gastrointestinal surgeries. If someone decides to join, they can expect to provide samples of their intestinal tissue and undergo monitoring to help researchers learn more about their gut health and its impact on polyp recurrence. This study is currently recruiting participants, and it aims to contribute valuable insights into preventing the recurrence of colorectal polyps.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients aged 40-75 years who undergo the colonoscopy with at least 1 advanced premalignant polyps or ≥ 3 adenoma
• Exclusion Criteria:
• • patient with severe physical diseases that prevented them from adhering to the examination requirements,
• • patient with coagulopathy or other contraindications for biopsy or polypectomy,
• • patient with previous surgical procedures on the gastrointestinal tract,
• • presence of colorectal cancer or other malignant tumor at baseline
• • presence of inflammatory bowel disease or hereditary polyposis syndromes (such as family adenomatous polyposis or Lynch syndrome)
• • within 1 month before enrollment, oral antibiotics and probiotics were taken;
• • inability to provide informed consent or refusal to participate in the study.